Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2005

View Archived Issues

PET scans may help predict response to therapy in metastatic breast cancer

Inhaled insulin shows promise as an alternative to subcutaneous insulin in type 1 diabetes

Novartis reflects on Q2 activities

Thymitaq phase III study fails to meet primary endpoint

Phase IIb studies begin for PT-141 for erectile dysfunction

Two more sites join Canadian phase II study of ADH-1

Par terminates amoxicillin partnership with Advancis

Characterization of a novel VRAC inhibitor for heart disease

KBMA vaccines: novel strategy for safe protective immunity

SB-706375: novel nonpeptidic UT receptor antagonist

Antithrombotic activity of DU-176b described in several animal models

Data describing pharmacodynamic profile of TGN-255 presented

Biogen Idec and PDL form collaboration for antibody products

Novel immunomodulatory agents disclosed in recent patents

Novel agents for thrombotic disorders prepared and tested

Novel agents for treating ADHD in early development at PsychoGenics

Novel MRI agents imparted by General Hospital Corporation

Santhera and Takeda to collaborate on idebenone for Friedreich's ataxia

Pozen discontinues MT-100 development in U.S. following FDA review

Pozen submits Trexima NDA for migraine

HIV protease inhibitors have potential efficacy against opportunistic leishmaniasis infections

European orphan drug status recommended for Amplimexon

Rohto to acquire Bayer Yakuhin research center

AstraZeneca and Astex Therapeutics partner on PKB inhibitors for cancer

ISIS-301012 reduces LDL cholesterol in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...